Tuesday, October 28, 2025
- 8:00AM-8:15AM
-
Abstract Number: 1722
Defining Safe Hydroxychloroquine Blood Levels: Time to Switch to Precision Monitoring for Optimized Lupus Care
Plenary III (1722–1727)- 8:15AM-8:30AM
-
Abstract Number: 1723
Impaired Maintenance of X-Chromosome Inactivation in B Cells, But Not T Cells, Exacerbates Interferon-Driven Systemic Autoimmunity
Plenary III (1722–1727)- 8:15AM-8:30AM
-
Abstract Number: PP09
The Role of a Palliative Care Support Team to Optimize Outcomes for Patients with Airway Involvement from Relapsing Polychondritis
(PP09-PP13) Patient Perspectives- 8:30AM-8:45AM
-
Abstract Number: PP10
Breaking Through Scleroderma’s Invisible Struggles: From Isolation to Connection
(PP09-PP13) Patient Perspectives- 8:30AM-8:45AM
-
Abstract Number: 1724
Pathogenic role of Mucosal-Associated Invariant T cells in Rheumatoid Arthritis.
Plenary III (1722–1727)- 8:45AM-9:00AM
-
Abstract Number: 1725
Functional NOTCH4 Variants Drive Vasculopathy and Fibrosis in Systemic Sclerosis.
Plenary III (1722–1727)- 8:45AM-9:00AM
-
Abstract Number: PP11
Lived Experience in Action: How Co-Creating a Psoriatic Arthritis Project Empowered My Journey as a Patient Advocate
(PP09-PP13) Patient Perspectives- 9:00AM-9:15AM
-
Abstract Number: PP12
From Invisibility to Advocacy: A Gout Patient’s Journey to Validation and Systemic Change
(PP09-PP13) Patient Perspectives- 9:00AM-9:15AM
-
Abstract Number: 1726
Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies
Plenary III (1722–1727)- 9:15AM-9:30AM
-
Abstract Number: 1727
Distribution of Fracture Risk Status and Osteoporosis Treatment Use Among Postmenopausal Women with Osteoporosis in the United States
Plenary III (1722–1727)- 9:15AM-9:30AM
-
Abstract Number: PP13
Life Transitions and Their Impact on Patients
(PP09-PP13) Patient Perspectives- 10:00AM-10:15AM
-
Abstract Number: 1740
A New Link Between Calprotectin, Cholesterol Efflux Dysfunction, and Premature Atherosclerosis in Juvenile Dermatomyositis
Abstracts: Pediatric Rheumatology – Clinical II (1740–1745)- 10:00AM-10:15AM
-
Abstract Number: 1764
Development and Validation of a Simulation Model for Induction of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Abstracts: Vasculitis – ANCA-Associated (1764–1769)- 10:00AM-10:15AM
-
Abstract Number: 1746
Inflammatory- and Fibrosis-Related Biomarkers and Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk